Not sure how you can assume one large pharma would develop more indications all at once vs NEU licensing out to multiple. The assumption is a dangerous one given pharma delay developing indications all the time, just look at Acadia and FragileX. A single company still has finite human resources required to progress these, regardless of MC.
Not sure how you can assume one large pharma would develop more...
-
- There are more pages in this discussion • 2,408 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.30 |
Change
-0.090(0.46%) |
Mkt cap ! $2.466B | |||
| Open | High | Low | Value | Volume |
| $19.55 | $19.65 | $18.88 | $10.53M | 549.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 4552 | $19.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.30 | 674 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |